| Literature DB >> 33758389 |
Matthew A Rysavy1, Tarah T Colaizy2, Carla M Bann3, Sara B DeMauro4, Andrea F Duncan4, Jane E Brumbaugh5, Myriam Peralta-Carcelen6, Heidi M Harmon2, Karen J Johnson2, Susan R Hintz7, Betty R Vohr8, Edward F Bell2.
Abstract
OBJECTIVE: Determine how neurodevelopmental impairment (NDI) relates to concurrent outcomes for children born extremely preterm. STUDYEntities:
Mesh:
Year: 2021 PMID: 33758389 PMCID: PMC7985590 DOI: 10.1038/s41372-021-00999-7
Source DB: PubMed Journal: J Perinatol ISSN: 0743-8346 Impact factor: 2.521
Classification of Neurodevelopmental Impairment.
| NDI classification | Characteristic | ||||
|---|---|---|---|---|---|
| Bayley-III Cognitive Score | GMFCS | CP | Vision impairment | Hearing impairment | |
| Severe | <70 | Level 4 or 5 | Severe | Bilateral <20/200, despite correction | Severe, bilateral, cannot be corrected |
| Moderate | 70–84 | Level 2 or 3 | Moderate | N/A | N/A |
| Potential/Mild | 85–99 | Level 1 or Possible Level 1 | Mild | N/A | N/A |
| No | ≥100 | Level 0 | No | N/A | N/A |
NDI classification was determined by the presence of the most severe characteristic that met criteria. For example, a child with bilateral blindness <20/200 was classified as having severe NDI regardless of Bayley-III cognitive score or diagnosis of CP.
The GMFCS examination was performed at follow-up for all children regardless of cerebral palsy diagnosis. Children with a cerebral palsy diagnosis therefore represent a subset of children with abnormal GMFCS examination. Cerebral palsy was defined as abnormality in the neuromuscular exam (except for isolated low tone) with associated functional impairment. Severity is based on GMFCS level (mild = level 1; moderate = level 2 or 3; severe = level 4 or 5).
NDI neurodevelopmental impairment, Bayley-III Bayley Scales of Infant and Toddler Development, third edition, GMFCS Gross Motor Function Classification Scale, CP cerebral palsy.
Rates of Each Component of Neurodevelopmental Impairment.
| Component | No NDI | Potential/Mild NDI | Moderate NDI | Severe NDI |
|---|---|---|---|---|
| ( | ( | ( | ( | |
| Bayley-III Cognitive | ||||
| Score 100+ | 825 (100) | 117 (7) | 3 (0) | 13 (3)a |
| Score 85–99 | – | 1459 (93) | 27 (4) | 27 (7)a |
| Score 70–84 | – | – | 627 (95) | 35 (9)a |
| Score <70 | – | – | – | 329 (81)a |
| GMFCS level | ||||
| Level 0 | 825 (100) | 1202 (76) | 407 (62) | 109 (26)b |
| Level 1c | – | 374 (24) | 170 (26) | 105 (25)b |
| Level 2–3 | – | – | 80 (12) | 122 (29)b |
| Level 4–5 | – | – | – | 88 (21)b |
| CP level | ||||
| None | 825 (100) | 1475 (94) | 541 (82) | 219 (52)b |
| Mild | – | 101 (6) | 76 (12) | 37 (9)b |
| Moderate | – | – | 40 (6) | 79 (19)b |
| Severe | – | – | – | 89 (21)b |
| Blindness | – | – | – | 51 (12)d |
| Deafness | – | – | – | 102 (24)e |
Bayley-III Bayley Scales of Infant and Toddler Development, third edition, GMFCS Gross Motor Function Classification Scale, CP cerebral palsy.
aOf 404 children (21 children with severe NDI did not have Bayley-III cognitive scores).
bOf 424 children (1 child with severe NDI did not have data on GMFCS score or CP).
cIncludes “possible level 1”.
dOf 421 children (4 children with severe NDI did not have data on vision).
eOf 423 children (2 children with severe NDI did not have data on hearing).
Subject characteristics by neurodevelopmental impairment.
| Characteristic | No NDI | Potential/Mild NDI | Moderate NDI | Severe NDI |
|---|---|---|---|---|
| ( | ( | ( | ( | |
| Mother | ||||
| Age < 20 years | 79 (10) | 182 (12) | 70 (11) | 47 (11) |
| Private insurance** | 450 (55) | 643 (41) | 208 (32) | 171 (40) |
| Received any prenatal care* | 795 (96) | 1509 (96) | 611 (93) | 406 (96) |
| Race/ethnicity** | ||||
| White non-Hispanic | 394 (48) | 605 (38) | 218 (33) | 154 (36) |
| Black non-Hispanic | 284 (35) | 619 (39) | 290 (44) | 178 (42) |
| White Hispanic | 78 (9) | 218 (14) | 103 (16) | 53 (12) |
| Black Hispanic | 6 (1) | 17 (1) | 4 (1) | 7 (2) |
| Other | 61 (7) | 115 (7) | 42 (6) | 33 (8) |
| Diabetesa | 39 (5) | 67 (4) | 28 (4) | 18 (4) |
| Hypertensionb | 173 (21) | 320 (20) | 148 (23) | 86 (20) |
| Clinical chorioamnionitis | 146 (18) | 297 (19) | 120 (18) | 90 (21) |
| Infant | ||||
| Male** | 359 (44) | 760 (48) | 339 (52) | 261 (62) |
| Multiple birth | 209 (25) | 362 (23) | 152 (23) | 101 (24) |
| 1-min Apgar score ≤ 3** | 361 (44) | 699 (44) | 314 (48) | 243 (57) |
| Birth weight (g)—median, [IQR]** | 790 (689–900) | 760 (660–870) | 725 (631–840) | 690 (589–808) |
| Small for gestational agec** | 27 (3) | 67 (4) | 44 (7) | 34 (8) |
| Antenatal steroidsd** | 756 (92) | 1407 (90) | 551 (85) | 368 (87) |
| Birth by c-section | 526 (64) | 1020 (65) | 424 (65) | 286 (67) |
| Gestational age at birth** | ||||
| 22 weeks | 1 (0) | 9 (1) | 10 (2) | 7 (2) |
| 23 weeks | 33 (4) | 114 (7) | 45 (7) | 61 (14) |
| 24 weeks | 147 (18) | 346 (22) | 162 (25) | 131 (31) |
| 25 weeks | 273 (33) | 501 (32) | 214 (33) | 134 (32) |
| 26 weeks | 371 (45) | 606 (38) | 226 (34) | 92 (22) |
| IVH grade 3–4 | 77 (9) | 198 (13) | 116 (18) | 140 (33) |
| Surgical NEC | 14 (2) | 60 (4) | 27 (4) | 43 (10) |
| ROP ≥ stage 3 | 118 (14) | 299 (19) | 180 (27) | 176 (41) |
| Severe BPDe | 153 (19) | 455 (29) | 231 (35) | 223 (53) |
All values in parentheses are percentages unless indicated otherwise.
NDI neurodevelopmental impairment, IQR interquartile range, IVH intraventricular hemorrhage, NEC necrotizing enterocolitis, ROP retinopathy of prematurity, BPD bronchopulmonary dysplasia.
*p value for comparison across all categories <0.05.
**p value for comparison across all categories <0.001.
aIncludes any diagnosis of diabetes during pregnancy.
bIncludes chronic hypertension, gestational hypertension, pre-eclampsia, and eclampsia.
cDefined as birth weight <10th percentile for age and sex.
dIncludes receipt of any antenatal dexamethasone or betamethasone for fetal maturation, regardless of timing relative to birth or whether a full or partial course was received.
eDefined as supplemental oxygen ≥30% or positive pressure.
Childhood Outcomes at 18–22 Months’ Corrected Age by Neurodevelopmental Impairment.
| Outcome | No NDI | Potential/Mild NDI | Moderate NDI | Severe NDI |
|---|---|---|---|---|
| ( | ( | ( | ( | |
| Medical care since NICU discharge | ||||
| Rehospitalized | 331 (40) | 733/1574 (47) | 328 (50) | 300 (71) |
| Mean number (SD) | 1.7 (1.3) | 2.0 (2.9) | 2.2 (2.1) | 3.2 (3.1) |
| Reason | ||||
| Respiratory | 154/327 (47) | 385/726 (53) | 186/322 (58) | 173/300 (58) |
| Neurologic | 3/327 (1) | 31/726 (4) | 17/322 (5) | 34/300 (11) |
| Surgery | 99/327 (30) | 184/726 (25) | 87/322 (27) | 103/300 (34) |
| Infection | 82/327 (25) | 149/726 (21) | 73/322 (23) | 77/300 (26) |
| Growth/Nutrition | 8/327 (2) | 43/726 (6) | 37/322 (11) | 37/300 (12) |
| Mean number of outpatient subspecialists (SD) | 2.8 (1.3) | 3.0 (1.4) | 3.2 (1.6) | 4.1 (1.5) |
| Surgeries since NICU discharge | ||||
| Tympanostomy tubes | 88/725 (12) | 149/1398 (11) | 55/583 (9) | 57/361 (16) |
| Tracheostomy | 3/725 (0) | 9/1398 (1) | 9/583 (2) | 27/361 (7) |
| Eye surgery | 37/725 (5) | 116/1398 (8) | 95/583 (16) | 85/361 (24) |
| Hernia surgery | 81/725 (11) | 166/1398 (12) | 68/583 (12) | 62/361 (17) |
| Gastrostomy tube | 15/725 (2) | 74/1398 (5) | 51/583 (9) | 82/361 (23) |
| Fundoplication | 7/725 (1) | 16/1398 (1) | 12/583 (2) | 23/361 (6) |
| Shunt for hydrocephalus | 3/725 (0) | 26/1398 (2) | 15/583 (3) | 41/361 (11) |
| Bronchoscopy | 16/725 (2) | 56/1398 (4) | 35/583 (6) | 50/361 (14) |
| Medication use during prior 3 months | ||||
| Anti-reflux | 64 (8) | 190 (12) | 121 (18) | 140 (33) |
| Asthma/BPD | 111/659 (17) | 239/1213 (20) | 117/487 (24) | 81/264 (31) |
| Anti-seizure | 2 (0) | 15 (1) | 15 (2) | 45 (11) |
| Thyroid hormone | 11 (1) | 19 (1) | 11 (2) | 16 (4) |
| Anti-spasticity | 0 (0) | 1 (0) | 6 (1) | 33 (8) |
| Current medical equipment | ||||
| Apnea monitor | 1 (0) | 22 (1) | 10 (2) | 23 (5) |
| Oxygen | 8 (1) | 37 (2) | 43 (7) | 92 (22) |
| Ventilator/CPAP | 0 (0) | 8 (1) | 13 (2) | 33 (8) |
| Wheelchair/adapted stroller | 0 (0) | 0 (0) | 5 (1) | 43 (10) |
| Braces/orthotics | 18 (2) | 96 (6) | 72 (11) | 113 (27) |
| Walker/stander | 1 (0) | 14 (1) | 24 (4) | 71 (17) |
| Corrective lenses | 24 (3) | 108 (7) | 72 (11) | 78 (19) |
| Hearing aids/cochlear implants | 8 (1) | 23 (1) | 13 (2) | 60 (14) |
| Current medical support services | ||||
| Visiting nurse | 17 (2) | 41 (3) | 36 (5) | 47 (11) |
| Home nurse | 6 (1) | 22 (1) | 38 (6) | 55 (13) |
| OT/PT | 138 (17) | 525 (33) | 307 (47) | 317 (75) |
| Speech therapy | 169 (21) | 428 (27) | 233 (36) | 223 (53) |
| Social worker | 49 (6) | 134 (9) | 90 (14) | 94 (22) |
| Current custody and child care arrangements | ||||
| Under state supervision | 25 (3) | 45 (3) | 38 (6) | 33 (8) |
| Center-based daycare | 131/824 (16) | 210/1565 (13) | 59/651 (9) | 25/416 (6) |
| Home-based daycare | 138/824 (17) | 196/1565 (13) | 58/651 (9) | 21/416 (5) |
| Babysitter/Au Pair | ||||
| Relative | 121 (15) | 228 (14) | 81 (12) | 51 (12) |
| Non-relative | 59 (7) | 69 (4) | 25 (4) | 16 (4) |
| Medical child carea | 4/824 (0) | 22/1565 (1) | 38/651 (6) | 45/416 (11) |
| Current feeding status | ||||
| Tube fed | 12 (1) | 67 (4) | 72 (11) | 133 (31) |
| Parenteral nutrition | 2 (0) | 5 (0) | 2 (0) | 5 (1) |
| Feeds self | 790 (96) | 1432 (91) | 525 (80) | 188 (44) |
All outcomes were significantly different (p < 0.05) across NDI categories after controlling for gestational age at birth (in weeks), except for parenteral nutrition.
NICU neonatal intensive care unit, SD standard deviation, BPD bronchopulmonary dysplasia, CPAP continuous positive airway pressure, OT occupational therapy, PT physical therapy.
aDefined as requiring nursing or other specialized supervision either at home or in a non-home facility.